Jianxia Guo

Jianxia Guo

Auto-generated profile, based on publicly available information

Jianxia Guo

Cancer Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2022 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
BKBrian F. Kiesel
Brian F. Kiesel
JGJianxia Guo
Jianxia Guo
RPRobert A. Parise
Robert A. Parise
RVRaman Venkataramanan
Raman Venkataramanan
DCDavid A. Clump
David A. Clump
JBJan H. Beumer
Jan H. Beumer
Purpose Ataxia telangiectasia and Rad3-related (ATR) initiates and regulates cellular responses to DNA damage, such as those caused by cancer treatments. Several ATR inhibitors (ATRi) are in clinical development including AZD6738. Therapeutic indices among ATRi may differ as a result of varying potencies and concentrations at both tumor and off-target sites. Additionally, AZD6738 contributes to anti-tumor immune responses necessitating evaluation of exposure at immunological sites. Methods Using mouse models and a highly sensitive LC–MS/MS assay, the pharmacokinetics of AZD6738 were studied, including dose linearity, bioavailability, metabolism, and tissue distribution in tumor-bearing mice. Results Initial studies identified dose-dependent bioavailability, with greater than proportional increases in exposure as dose increased resulting in a ~ twofold increase in bioavailability between the lowest and highest investigated doses. These behaviors were successfully captured with a compartmental PK model. Analysis of metabolite PK revealed decreasing metabolic ratios with increasing dose, indicative of saturable first-pass metabolism. Further analysis revealed that intestinal and gut metabolism contribute to metabolism and these saturable mechanisms. Studies of tumor and tissue distribution found rapid and extensive drug distribution to most tissues except brain and spinal cord. Conclusion The complex non-linear behavior of AZD6738 PK in mice was due to pre-systemic saturation and which appears to be recapitulated clinically at low doses. PK reported here will allow future correlation of tissue related toxicities with drug exposure as well as exposure with immunological responses. These results can also be compared with those from similar studies of other ATRi to contrast drug exposure with responses.

7 July 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
JHJulianne L. Holleran
Julianne L. Holleran
RPRobert A. Parise
Robert A. Parise
JGJianxia Guo
Jianxia Guo
BKBrian F. Kiesel
Brian F. Kiesel
STSarah Elizabeth Taylor
Sarah Elizabeth Taylor
JBJan H. Beumer
Jan H. Beumer

18 September 2020 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
AJAnand Joshi
Anand Joshi
JGJianxia Guo
Jianxia Guo
JHJulianne L. Holleran
Julianne L. Holleran
BKBrian Kiesel
Brian Kiesel
STSarah Elizabeth Taylor
Sarah Elizabeth Taylor
JBJan H. Beumer
Jan H. Beumer